Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cisco Systems Inc (CSCO) vs Viatris Inc (VTRS) Price & Performance

Cisco Systems IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Cisco Systems Inc vs Viatris Inc — how do they compare? Cisco Systems Inc trades at $116.04 (market cap $452.96B), while Viatris Inc trades at $17.47 (market cap $20.03B). The key difference: Cisco Systems Inc is far larger — about 22.6× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Cisco Systems Inc for 86 Days and Viatris Inc for 57 Days on average.

CSCOVTRS
Market Cap
$452.96B$20.03B
Volume
12,951,57814,109,977
Sector
TechnologyHealth
52-Week High
$130.00$18.27
52-Week Low
$67.46$9.74
Typical Hold Time
86 Days57 Days
Enterprise Value
$466.58B$32.15B
Dividend Yield
1.46%2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cisco Systems Inc

Cisco Systems (CSCO) trades at $114.89, down 2.59% on the day, as the stock consolidates near recent highs. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $1.22 versus $1.17, continuing a trend of earnings outperformance. Technical indicators show a bullish moving average trend while oscillators suggest potential near-term consolidation. Recent news highlights Cisco's AI-driven networking momentum with Splunk integration and partnerships with NVIDIA, supporting multi-year growth prospects in AI infrastructure.

Cisco presents a compelling investment case with robust profitability metrics (64.52% gross margin, 27.32% ROE) and analyst consensus pointing to 13% upside to the $129.77 price target. Key risks include competitive pressure in AI security from Datadog and CrowdStrike, and the stock's elevated valuation multiples (P/E 35.25, P/S 7.39) that require continued execution. The company's strong cash flow generation and dividend payments provide shareholder value support.

Viatris Inc

Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.

The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CSCO
18% Buy82% Sell
Avg holding period · 86 Days
VTRS

No sentiment data available yet.

Top news

Latest headlines on both assets

About Cisco Systems Inc

Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.

Read more on CSCO →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →